Literature DB >> 17522860

Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer.

Lisa H Butterfield1, Antoni Ribas, Douglas M Potter, James S Economou.   

Abstract

We are investigating the use of Alpha Fetoprotein (AFP) as a tumor rejection antigen for hepatocellular carcinoma (HCC). We recently completed vaccination of 10 AFP+/HLA-A2.1+ HCC subjects with AFP peptide-pulsed autologous dendritic cells (DC). There were increased frequencies of circulating AFP-specific T cells and of IFNgamma-producing AFP-specific T cells after vaccination. In order to better understand the lack of association between immune response and clinical response, we have examined additional aspects of the AFP immune response in patients. Here, we have characterized the cell surface phenotype of circulating AFP tetramer-positive CD8 T cells and assessed AFP-specific CD4 function. Before vaccination, HCC subjects had increased frequencies of circulating AFP-specific CD8 T cells with a range of naïve, effector, central and effector memory phenotypes. Several patients had up-regulated activation markers. A subset of patients was assessed for phenotypic changes pre- and post-vaccination, and evidence for complete differentiation to effector or memory phenotype was lacking. CD8 phenotypic and cytokine responses did not correlate with level of patient serum AFP antigen (between 74 and 463,040 ng/ml). Assessment of CD4+ T cell responses by ELISPOT and multi-cytokine assay did not identify any spontaneous CD4 T cell responses to this secreted protein. These data indicate that there is an expanded pool of partially differentiated AFP-specific CD8 T cells in many of these HCC subjects, but that these cells are largely non-functional, and that a detectable CD4 T cell response to this secreted oncofetal antigen is lacking.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522860     DOI: 10.1007/s00262-007-0337-9

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

1.  Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.

Authors:  Yang Liu; Lisa H Butterfield; Xiaohui Fu; Zhenshun Song; Xiaoping Zhang; Chongde Lu; Guanghui Ding; Mengchao Wu
Journal:  Int J Oncol       Date:  2011-04-13       Impact factor: 5.650

Review 2.  Current status and perspectives of immune-based therapies for hepatocellular carcinoma.

Authors:  Maridi Aerts; Daphné Benteyn; Hans Van Vlierberghe; Kris Thielemans; Hendrik Reynaert
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  A functional insertion/deletion polymorphism in the proximal promoter of CD3G is associated with susceptibility for hepatocellular carcinoma in Chinese population.

Authors:  Lingling Jiang; Jingya Xu; Jianqiang Ni; Xueren Gao; Zhansheng Zhu; Dong Dong; Xiaoshu Wang; Chunhua Shi; Xiaoyang Tao; Wanli Dong; Yuzhen Gao
Journal:  DNA Cell Biol       Date:  2012-06-25       Impact factor: 3.311

4.  Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.

Authors:  Dai Liu; Guangfu Li; Diego M Avella; Eric T Kimchi; Jussuf T Kaifi; Mark P Rubinstein; E Ramsay Camp; Don C Rockey; Todd D Schell; Kevin F Staveley-O'Carroll
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

5.  Alpha-fetoprotein specific CD4 and CD8 T cell responses in patients with hepatocellular carcinoma.

Authors:  Shahriar Behboudi; Stephen P Pereira
Journal:  World J Hepatol       Date:  2010-07-27

6.  Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects.

Authors:  Shiroh Tanoue; Li-Yuan Chang; Yonghai Li; David E Kaplan
Journal:  Cell Immunol       Date:  2015-02-25       Impact factor: 4.868

Review 7.  Dendritic cells based immunotherapy.

Authors:  Na Shang; Matteo Figini; Junjie Shangguan; Bin Wang; Chong Sun; Liang Pan; Quanhong Ma; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2017-10-01       Impact factor: 6.166

Review 8.  Immunotherapy of cancer in 2012.

Authors:  John M Kirkwood; Lisa H Butterfield; Ahmad A Tarhini; Hassane Zarour; Pawel Kalinski; Soldano Ferrone
Journal:  CA Cancer J Clin       Date:  2012-05-10       Impact factor: 508.702

9.  Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease.

Authors:  S Behboudi; A Alisa; S Boswell; J Anastassiou; A A Pathan; R Williams
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

10.  Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity.

Authors:  Jing-Yue Yang; Xiao Li; Li Gao; Zeng-Hui Teng; Wen-Chao Liu
Journal:  Exp Ther Med       Date:  2012-07-06       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.